This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinicaltrial data published in the European Journal of Pain. Adverse events were mostly mild and resolved spontaneously.
The study is expected to be the world’s first Phase 2a clinicaltrial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgia. The open-label Phase 2a clinicaltrial will evaluate the efficacy of TRYP-8802, an oral formulation of synthetic psilocybin, in tandem with psychotherapy for treating fibromyalgia.
The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain.
” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.
Nasdaq:HUGE) (CSE:HUGE) (FRA:0K9) (the “ Company ” or “ FSD ”) announced today that it intends to terminate the Phase 2 clinicaltrial of ultra-micronized palmitoylethanolamide (“PEA”), or FSD-201, for use in treating COVID-19. TORONTO–(BUSINESS WIRE)–FSD Pharma Inc.
“Our goal with this study is to enhance the existing treatment’s efficacy through adding CBD to create a new standard of care, potentially improving and extending glioblastoma patients’ quality of life.” These statements relate to future events or future performance. Chief Medical Officer, Enveric Biosciences.
Post-Traumatic Stress Disorder (PTSD) is a multifaceted mental health condition triggered by experiencing or witnessing traumatic events, persistently manifesting in symptoms like flashbacks, severe anxiety, and disrupted sleep. Looking ahead, the future of medical cannabis in PTSD treatment hinges on overcoming these challenges.
Consequently, psychedelics have received a significant amount of attention for ailments that are in need of more effective solutions, such as treatment-resistant depression (TRD). Exploring Psilocybin and Treatment-Resistant Depression. Future Trials With COMP360 Psilocybin.
This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinicaltrials for the purposes of novel drug development. The global chronic pain treatment market is predicted to progress at a CAGR of 6.5% from 2020 to 2030 and generate revenue of $151.7
(OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinicaltrial on neuropathic and post-operative pain. ” About The Study.
(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).
. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a ClinicalTrial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinicaltrial for INM-755 in healthy volunteers. Most types of epidermolysis bullosa are inherited. About INM-755.
. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a ClinicalTrial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinicaltrial for INM-755 in healthy volunteers. Most types of epidermolysis bullosa are inherited. About INM-755.
It is also crucial so that the correct data is collected in order to inform further research and clinicaltrials that are necessary for cannabis medicines to reach the UK National Health Service. The idea behind the MDT series is to place the unfamiliar cannabis medicines into a familiar case discussion format.
For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinicaltrial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinicaltrial.
” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.
According to the American Psychiatric Association , PTSD is a “psychiatric disorder that may occur in people who have experienced or witnessed a traumatic event such as natural disaster, as a serious accident, a terrorist act, war/combat or rape or who have been threatened with death, sexual violence or serious injury”.
Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic. million, or $0.79 million, or $2.61
(NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is pleased to announce that it has signed an agreement to begin scientific clinicaltrials globally. Forward-looking statements are only predictions. Investor Relations: Evan Veryard.
(USOTC: PAOG) cited a British Medical Journal case study report published today on the effectiveness of CBD in the treatment of lung cancer and COPD as validation of PAOG’s ongoing research and development of its own respiratory disorder treatment under the name RespRx. 9,199,960).
The longitudinal study showed that individuals who used artisanal cannabidiol (CBD) products reported better quality of life, lower psychiatric symptom severity and fewer medication-related adverse events compared with those not using CBD. This study represents a refreshing collaboration of scientists, clinicians, patients and advocates.
CBD has been suggested to act as a treatment for sclerosis symptoms, as well as epilepsy among children. Apart from this, various clinicaltrials are done for multiple conditions. The triggers are events that happen before the seizure starts. Is CBD an effective treatment for people with seizures and epilepsy?
(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood. 3 Nature Aging | VOL 1 | July 2021 | p. 616–623.
The cannabinoid receptor known as CB1 , which occurs in heavy concentration in the brain, was identified as playing a role in pathophysiological events ranging from memory deficits to neurodegenerative disorders. In their summary, the study’s authors noted that. CBD alone is sufficiently effective in enhancing fracture healing.
of their dry weight and it is not practical to obtain meaningful pure amounts of these compounds from the flesh of mushrooms, at a reasonable cost, to conduct clinicaltrials in humans and to commercialize these products. The levels of these compounds in dried mushrooms are only 0.2% – 1.0% ” About Nova Mentis Life Science Corp.
Dr. Goldstein: We don’t have clinicaltrials to say, yes this is definitively beneficial or detrimental for children. But we may be on the cusp of having those trials, which would be very exciting. CannMed: I’m glad you brought up ADHD. Full disclosure: my son has been diagnosed with ADHD.
Medical marijuana is a potential treatment for insomnia, and it offers an alternative to traditional pharmaceuticals. It is often caused by life events such as stress, anxiety, or a significant change in routine. Chronic insomnia often requires a more comprehensive treatment approach.
A number of clinicaltrials have been investigating the potential of psychedelics in mental health treatment. Following research findings here and abroad, the application sought to have the drugs used as part of psychotherapy treatment for mental illnesses, depression and post-traumatic stress disorder.
This SRA will leverage four other clinicaltrials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, Bipolar disorder, and chronic back pain. The goal at TrPR is to accelerate progress towards impactful and accessible psychedelic treatments.
(Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announces that the first patient has been dosed in a Phase 2 proof-of-concept clinical study investigating ANEB-001 as a potential treatment for acute cannabinoid intoxication.
ClinicalTrial Sample Size. The trial was conducted with just 186 participants, which is far too small of a sample size to provide findings generalizable to the larger population. a necessary question to address as medical marijuana becomes more accessible. Daily Cannabis Use as a Disqualifier.
“Lucid has successfully developed a strong pipeline of novel therapeutic compounds — supported by IP in order to advance to future clinicaltrials — and we are confident that the experience the Lucid leadership team brings will allow us to immediately start the process towards clinicaltrials to further advance these promising therapies.
Additionally, this novel antibody conjugate demonstrated very good tolerability during this DLT phase 1 trial. Clinicaltrial information: NCT03276572 ( [link] ). Abstract Number: 5015. Date and Time: Available Starting June 4, 2021 , 9:00 am (EST). The full ASCO meeting program is available at: www.asco.org.
The study, titled Pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial , was first published by NORML. Adverse events were mostly mild and resolved spontaneously.
It turns out that this blissful drug, MDMA, has the potential to be used effectively as a treatment for certain conditions- some of which are in urgent need of effective medical assistance. . MDMA has also reportedly been used with over 1,000 individuals in clinicaltrials , with no adverse effects to report. . What is MDMA?
5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. May not be reprinted without permission from the source. 2021.06.005.
. “Nearly 100,000 people in the United States have idiopathic pulmonary fibrosis (IPF), and although cases continue to climb, there is still a significant unmet need in treatment options for this chronic disease,” said Chris Chapman, M.D., President, Director and Chief Medical Officer. Investor Contact: Robert Schatz. 646) 421-9523.
Some clinical studies have evaluated the safety and efficacy of cannabinoid-based medicines for the treatment of autism spectrum disorder (ASD). Some of these studies have shown positive results, but adverse events were also noted. Fletcher S.
“These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinicaltrials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.”
This is according to a study published in the Journal of Clinical Medicine Research and epublished by the U.S. For the study researchers with the Nordic Cannabis Research Institute in Denmark reviewed 25 clinicaltrials assessing the safety and efficacy of CBD in various populations. National Institute of Health.
While there is a need for more clinicaltrials on the subject, users and alternative-therapy practitioners worldwide continue to buy cannabis seeds online for healing physical and mental ailments. Marijuana’s potential role in the treatment of PTSD and other anxiety-related disorders has long been of interest to researchers worldwide.
The distribution of clinicaltrials across Phase I-IV indicates that the majority of trials for FXS have been in the early and midphases of development, with 77% of trials in Phase I-II, and only 23% in Phase III-IV. The US has a substantial lead in the number of FXS clinicaltrials globally. KEY TAKEAWAYS.
We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., at the end of the 17 weeks of ganaxolone treatment.
Clinicaltrials repeatedly demonstrate their promise for treating mood, anxiety, and substance use disorders. In 2017, the FDA designated MDMA a breakthrough therapy for post-traumatic stress disorder, and in 2018 the agency identified psilocybin as a breakthrough for treatment-resistant depression.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content